{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:14:52Z","timestamp":1790612092331,"version":"4.1.0"},"reference-count":50,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"published-print":{"date-parts":[[2019,4,29]]},"abstract":"<jats:p>Ankylosing spondylitis (AS) is associated with accelerated atherosclerosis and enhanced cardiovascular morbidity and mortality compared to the general population. The mechanisms and mediators of this phenomenon have not been fully explained, but an expanding body of evidence demonstrates that increased cardiovascular risk in AS is heralded by endothelial dysfunction. We performed a literature review using the PubMed database from the year 2006 up to 2018. In this article we review the epidemiology, current evidence for impaired endothelial function, potential mechanisms and markers controlling this dysfunction, and finally we summarize the data regarding the efficacy of pharmacotherapy in reducing endothelial dysfunction in patients suffering from AS.<\/jats:p>","DOI":"10.5114\/reum.2019.84815","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T11:36:16Z","timestamp":1557920176000},"page":"100-105","source":"Crossref","is-referenced-by-count":19,"title":["Endothelial dysfunction in patients with ankylosing spondylitis"],"prefix":"10.5114","volume":"57","author":[{"given":"Katarzyna","family":"\u0141osi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Korkosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kwa\u015bny-Krochin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"ref-776107","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean LE","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, et al. (2014). Global prevalence of ankylosing spondylitis Rheumatology (Oxford). 53: 650-657.","journal-title":"Rheumatology (Oxford)"},{"key":"ref-776108","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados M","year":"2011","unstructured":"Dougados M, Baeten D. (2011). Spondyloarthritis Lancet. 377: 2127-2137.","journal-title":"Lancet"},{"key":"ref-776109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/ard.52.3.174","article-title":"Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis","volume":"52","author":"Lehtinen K","year":"1993","unstructured":"Lehtinen K. (1993). Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis Ann Rheum Dis. 52: 174-176.","journal-title":"Ann Rheum Dis"},{"key":"ref-776110","first-page":"S80","article-title":"Mortality in ankylosing spondylitis","volume":"26","author":"Zochling J","year":"2008","unstructured":"Zochling J, Braun J. (2008). Mortality in ankylosing spondylitis Clin Exp Rheumatol. 26: S80-84.","journal-title":"Clin Exp Rheumatol"},{"key":"ref-776111","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/heartjnl-2015-307838","article-title":"Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders","volume":"102","author":"Agca R","year":"2016","unstructured":"Agca R, Heslinga SC, van Halm VP, et al. (2016). Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders Heart. 102: 790-795.","journal-title":"Heart"},{"key":"ref-776112","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson K","year":"2017","unstructured":"Bengtsson K, Forsblad-d\u2019Elia H, Lie E, et al. (2017). Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study Arthritis Res Ther. 19: 102.","journal-title":"Arthritis Res Ther"},{"key":"ref-776113","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr.20408","article-title":"Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis","volume":"63","author":"Bremander A","year":"2011","unstructured":"Bremander A, Petersson IF, Bergman S, et al. (2011). Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis Arthritis Care Res (Hoboken). 63: 550-556.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref-776114","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/acr.22512","article-title":"Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study","volume":"67","author":"Wright KA","year":"2015","unstructured":"Wright KA, Crowson CS, Michet CJ, et al. (2015). Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study Arthritis Care Res (Hoboken). 67: 836-841.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref-776115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/annrheumdis-2016-209315","article-title":"Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?","volume":"76","author":"Eriksson JK","year":"2017","unstructured":"Eriksson JK, Jacobsson L, Bengtsson K, et al. (2017). Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 76: 364-370.","journal-title":"Ann Rheum Dis"},{"key":"ref-776116","doi-asserted-by":"crossref","first-page":"H2","DOI":"10.1152\/ajpheart.00471.2010","article-title":"Assessment of flow-mediated dilation in humans: a methodological and physiological guideline","volume":"300","author":"Thijssen DHJ","year":"2011","unstructured":"Thijssen DHJ, Black MA, Pyke KE, et al. (2011). Assessment of flow-mediated dilation in humans: a methodological and physiological guideline Am J Physiol Heart Circ Physiol. 300: H2-12.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref-776117","doi-asserted-by":"crossref","first-page":"e004979","DOI":"10.1161\/CIRCIMAGING.116.004979","article-title":"Microvascular function contributes to the relation between aortic stiffness and cardiovascular events: the Framingham Heart Study","volume":"9","author":"Cooper LL","year":"2016","unstructured":"Cooper LL, Palmisano JN, Benjamin EJ, et al. (2016). Microvascular function contributes to the relation between aortic stiffness and cardiovascular events: the Framingham Heart Study Circ Cardiovasc Imaging. 9: e004979.","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref-776118","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1172\/JCI117852","article-title":"Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis","volume":"95","author":"Quyyumi AA","year":"1995","unstructured":"Quyyumi AA, Dakak N, Andrews NP, et al. (1995). Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis Clin Invest. 95: 1747-1755.","journal-title":"Clin Invest"},{"key":"ref-776119","first-page":"109","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada S","year":"1991","unstructured":"Moncada S, Palmer RMJ, Higgs EA. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol Rev. 43: 109-142.","journal-title":"Pharmacol Rev"},{"key":"ref-776120","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0735-1097(96)00325-7","article-title":"Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers","volume":"28","author":"Kugiyama K","year":"1996","unstructured":"Kugiyama K, Yasue H, Ohgushi M, et al. (1996). Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers J Am Coll Cardiol. 28: 1161-1167.","journal-title":"J Am Coll Cardiol"},{"key":"ref-776121","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5830\/CVJA-2011-068","article-title":"Endothelial dysfunction: the early predictor of atherosclerosis","volume":"23","author":"Mudau M","year":"2012","unstructured":"Mudau M, Genis A, Lochner A, et al. (2012). Endothelial dysfunction: the early predictor of atherosclerosis Cardiovasc J Afr. 23: 222-231.","journal-title":"Cardiovasc J Afr"},{"key":"ref-776122","doi-asserted-by":"crossref","first-page":"792090","DOI":"10.1155\/2013\/792090","article-title":"Functionally defective high-density lipoprotein and paraoxonase: A couple for endothelial dysfunction in atherosclerosis","volume":"2013","author":"Eren E","year":"2013","unstructured":"Eren E, Yilmaz N, Aydin O. (2013). Functionally defective high-density lipoprotein and paraoxonase: A couple for endothelial dysfunction in atherosclerosis Cholesterol. 2013: 792090.","journal-title":"Cholesterol"},{"key":"ref-776123","doi-asserted-by":"crossref","first-page":"L40","DOI":"10.1016\/S0002-9149(02)02963-6","article-title":"Endothelial function: From vascular biology to clinical applications","volume":"90","author":"Behrendt D","year":"2002","unstructured":"Behrendt D, Ganz P. (2002). Endothelial function: From vascular biology to clinical applications Am J Cardiol. 90: L40-L48.","journal-title":"Am J Cardiol"},{"key":"ref-776124","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.0000051384.43104.FC","article-title":"Endothelial dysfunction: A marker of atherosclerotic risk","volume":"23","author":"Bonetti PO","year":"2003","unstructured":"Bonetti PO, Lerman LO, Lerman A. (2003). Endothelial dysfunction: A marker of atherosclerotic risk Arterioscler Thromb Vasc Biol. 23: 168-175.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref-776125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/07853890701854702","article-title":"Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction","volume":"40","author":"Munzel T","year":"2008","unstructured":"Munzel T, Sinning C, Post F, et al. (2008). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction Ann Med. 40: 180-196.","journal-title":"Ann Med"},{"key":"ref-776126","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1161\/CIRCULATIONAHA.106.678276","article-title":"Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study","volume":"115","author":"Yeboah J","year":"2007","unstructured":"Yeboah J, Crouse JR, Hsu F-C, et al. (2007). Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study Circulation. 115: 2390-2397.","journal-title":"Circulation"},{"key":"ref-776127","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","article-title":"Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease","volume":"101","author":"Sch\u00e4chinger V","year":"2000","unstructured":"Sch\u00e4chinger V, Britten MB, Zeiher AM. (2000). Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation. 101: 1899-1906.","journal-title":"Circulation"},{"key":"ref-776128","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/hc4601.099485","article-title":"Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease","volume":"104","author":"Heitzer T","year":"2001","unstructured":"Heitzer T, Schlinzig T, Krohn K, et al. (2001). Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease Circulation. 104: 2673-2678.","journal-title":"Circulation"},{"key":"ref-776129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kei145","article-title":"Impaired endothelial function in patients with ankylosing spondylitis","volume":"45","author":"Sari I","year":"2006","unstructured":"Sari I, Okan T, Akar S, et al. (2006). Impaired endothelial function in patients with ankylosing spondylitis Rheumatology (Oxford). 45: 283-286.","journal-title":"Rheumatology (Oxford)"},{"key":"ref-776130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3899\/jrheum.100668","article-title":"Assessment of subclinical vascular disease associated with ankylosing spondylitis","volume":"38","author":"Bodnar N","year":"2011","unstructured":"Bodnar N, Kerekes G, Seres I, et al. (2011). Assessment of subclinical vascular disease associated with ankylosing spondylitis J Rheumatol. 38: 723-729.","journal-title":"J Rheumatol"},{"key":"ref-776131","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-017-1439-1","article-title":"Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis","volume":"19","author":"Deyab G","year":"2017","unstructured":"Deyab G, Hokstad I, Whist JE, et al. (2017). Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis Arthritis Res Ther. 19: 232.","journal-title":"Arthritis Res Ther"},{"key":"ref-776132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.injr.2015.02.002","article-title":"Increased prevalence of subclinical atherosclerosis in ankylosing spondylitis","volume":"10","author":"Sharma SK","year":"2015","unstructured":"Sharma SK, Prasad KT, Handa R, et al. (2015). Increased prevalence of subclinical atherosclerosis in ankylosing spondylitis Indian J Rheumatol. 10: 53-57.","journal-title":"Indian J Rheumatol"},{"key":"ref-776133","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.berh.2016.10.006","article-title":"Cardiovascular disease in inflammatory rheumatic diseases","volume":"30","author":"Castaneda S","year":"2016","unstructured":"Castaneda S, Nurmohamed MT, Gonzalez-Gay MA. (2016). Cardiovascular disease in inflammatory rheumatic diseases Best Pract Res Clin Rheumatol. 30: 851-869.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref-776134","first-page":"612","article-title":"Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis","volume":"31","author":"Papagoras C","year":"2013","unstructured":"Papagoras C, Voulgari PV, Drosos AA. (2013). Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis Clin Exp Rheumatol. 31: 612-620.","journal-title":"Clin Exp Rheumatol"},{"key":"ref-776135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(97)00189-7","article-title":"Endothelial dysfunction: Does it matter? Is it reversible?","volume":"30","author":"Celermajer DS","year":"1997","unstructured":"Celermajer DS. (1997). Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol. 30: 325-333.","journal-title":"J Am Coll Cardiol"},{"key":"ref-776136","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms150711324","article-title":"Endothelial dysfunction in chronic inflammatory diseases","volume":"15","author":"Steyers CM","year":"2014","unstructured":"Steyers CM, Miller FJJ. (2014). Endothelial dysfunction in chronic inflammatory diseases Int J Mol Sci. 15: 11324-11349.","journal-title":"Int J Mol Sci"},{"key":"ref-776137","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00296-010-1416-3","article-title":"Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis","volume":"30","author":"Azevedo VF","year":"2010","unstructured":"Azevedo VF, Pecoits-Filho R. (2010). Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis Rheumatol Int. 30: 1411-1416.","journal-title":"Rheumatol Int"},{"key":"ref-776138","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10067-010-1589-x","article-title":"Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study","volume":"30","author":"Erre GL","year":"2011","unstructured":"Erre GL, Sanna P, Zinellu A, et al. (2011). Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study Clin Rheumatol. 30: 21-27.","journal-title":"Clin Rheumatol"},{"key":"ref-776139","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jbspin.2010.05.009","article-title":"Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters","volume":"78","author":"Kemeny-Beke A","year":"2011","unstructured":"Kemeny-Beke A, Gesztelyi R, Bodnar N, et al. (2011). Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters Joint Bone Spine. 78: 184-187.","journal-title":"Joint Bone Spine"},{"key":"ref-776140","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2169\/internalmedicine.48.2193","article-title":"Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis","volume":"48","author":"Sari I","year":"2009","unstructured":"Sari I, Kebapcilar L, Alacacioglu A, et al. (2009). Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis Intern Med. 48: 1363-1368.","journal-title":"Intern Med"},{"key":"ref-776141","first-page":"844","article-title":"Endothelial dysfunction is independent of inflammation and altered CCR7 T cell expression in patients with ankylosing spondylitis","volume":"35","author":"Sulicka J","year":"2017","unstructured":"Sulicka J, Surdacki A, Korkosz M, et al. (2017). Endothelial dysfunction is independent of inflammation and altered CCR7 T cell expression in patients with ankylosing spondylitis Clin Exp Rheumatol. 35: 844-849.","journal-title":"Clin Exp Rheumatol"},{"key":"ref-776142","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3899\/jrheum.141018","article-title":"Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study","volume":"42","author":"Berg IJ","year":"2015","unstructured":"Berg IJ, Van Der Heijde D, Dagfinrud H, et al. (2015). Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study J Rheumatol. 42: 645-653.","journal-title":"J Rheumatol"},{"key":"ref-776143","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/ijms17081255","article-title":"Serum interleukin-18, fetuin-A, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome","volume":"17","author":"Przepiera-B\u0119dzak H","year":"2016","unstructured":"Przepiera-B\u0119dzak H, Fischer K, Brzosko M. (2016). Serum interleukin-18, fetuin-A, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome Int J Mol Sci. 17: 1255.","journal-title":"Int J Mol Sci"},{"key":"ref-776144","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1756-185X.12487","article-title":"Endothelial progenitor cell biology in ankylosing spondylitis","volume":"18","author":"Verma I","year":"2015","unstructured":"Verma I, Syngle A, Krishan P. (2015). Endothelial progenitor cell biology in ankylosing spondylitis Int J Rheum Dis. 18: 336-340.","journal-title":"Int J Rheum Dis"},{"key":"ref-776145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0036-1593445","article-title":"Endothelial Progenitor Cells as a Marker of Endothelial Dysfunction and Atherosclerosis in Ankylosing Spondylitis: A Cross-Sectional Study","volume":"26","author":"Verma I","year":"2017","unstructured":"Verma I, Syngle A, Krishan P, et al. (2017). Endothelial Progenitor Cells as a Marker of Endothelial Dysfunction and Atherosclerosis in Ankylosing Spondylitis: A Cross-Sectional Study Int J Angiol. 26: 36-42.","journal-title":"Int J Angiol"},{"key":"ref-776146","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00296-012-2631-x","article-title":"IL-8 but no other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents","volume":"33","author":"Azevedo VF","year":"2013","unstructured":"Azevedo VF, Faria-Neto JR, Stinghen A, et al. (2013). IL-8 but no other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents Rheumatol Int. 33: 1779-1783.","journal-title":"Rheumatol Int"},{"key":"ref-776147","article-title":"Low vaspin levels are related to endothelial dysfunction in patients with ankylosing spondylitis","volume":"49","author":"Wang HH","year":"2016","unstructured":"Wang HH, Wang QF. (2016). Low vaspin levels are related to endothelial dysfunction in patients with ankylosing spondylitis Braz J Med Biol Res. 49.","journal-title":"Braz J Med Biol Res"},{"key":"ref-776148","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3899\/jrheum.111073","article-title":"Evaluation of circulating endothelial and platelet microparticles in men with ankylosing spondylitis","volume":"39","author":"Sari I","year":"2012","unstructured":"Sari I, Bozkaya G, Kirbiyik H, et al. (2012). Evaluation of circulating endothelial and platelet microparticles in men with ankylosing spondylitis J Rheumatol. 39: 594-599.","journal-title":"J Rheumatol"},{"key":"ref-776149","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11239-011-0663-9","article-title":"Does anti-TNF therapy cause any change in platelet activation in ankylosing spondylitis patients? A comparative study","volume":"33","author":"Or\u00fcm H","year":"2012","unstructured":"Or\u00fcm H, Pamuk GE, Pamuk ON, et al. (2012). Does anti-TNF therapy cause any change in platelet activation in ankylosing spondylitis patients? A comparative study J Thromb Thrombolysis. 33: 154-159.","journal-title":"J Thromb Thrombolysis"},{"key":"ref-776150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacc.2008.08.074","article-title":"Persistent Impairment of Endothelial Vasomotor Function Has a Negative Impact on Outcome in Patients With Coronary Artery Disease","volume":"53","author":"Kitta Y","year":"2009","unstructured":"Kitta Y, Obata J, Nakamura T, et al. (2009). Persistent Impairment of Endothelial Vasomotor Function Has a Negative Impact on Outcome in Patients With Coronary Artery Disease J Am Coll Cardiol. 53: 323-330.","journal-title":"J Am Coll Cardiol"},{"key":"ref-776151","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00296-015-3314-1","article-title":"Anti-TNF-alpha therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients","volume":"35","author":"Genre F","year":"2015","unstructured":"Genre F, Lopez-Mejias R, Miranda-Filloy JA, et al. (2015). Anti-TNF-alpha therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients Rheumatol Int. 35: 2069-2078.","journal-title":"Rheumatol Int"},{"key":"ref-776152","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10067-010-1402-x","article-title":"Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade","volume":"29","author":"Syngle A","year":"2010","unstructured":"Syngle A, Vohra K, Sharma A, et al. (2010). Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade Clin Rheumatol. 29: 763-770.","journal-title":"Clin Rheumatol"},{"key":"ref-776153","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.2007.086777","article-title":"Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade","volume":"68","author":"van Eijk","year":"2009","unstructured":"van Eijk IC, Peters MJL, Serne EH, et al. (2009). Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade Ann Rheum Dis. 68: 362-366.","journal-title":"Ann Rheum Dis"},{"key":"ref-776154","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10067-015-2912-3","article-title":"Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis","volume":"34","author":"Garg N","year":"2015","unstructured":"Garg N, Krishan P, Syngle A. (2015). Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis Clin Rheumatol. 34: 1065-1071.","journal-title":"Clin Rheumatol"},{"key":"ref-776155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13075-015-0795-y","article-title":"Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: Results from the RORA-AS statin intervention study","volume":"17","author":"Ikdahl E","year":"2015","unstructured":"Ikdahl E, Hisdal J, Rollefstad S, et al. (2015). Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: Results from the RORA-AS statin intervention study Arthritis Res Ther. 17: 279.","journal-title":"Arthritis Res Ther"},{"key":"ref-776156","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10067-013-2233-3","article-title":"Spironolactone improves endothelial dysfunction in ankylosing spondylitis","volume":"32","author":"Syngle A","year":"2013","unstructured":"Syngle A, Vohra K, Khichi D, et al. (2013). Spironolactone improves endothelial dysfunction in ankylosing spondylitis Clin Rheumatol. 32: 1029-1036.","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":["Zaburzenia funkcji \u015br\u00f3db\u0142onka u pacjent\u00f3w z zesztywniaj\u0105cym zapaleniem staw\u00f3w kr\u0119gos\u0142upa."],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-108996-85799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-108996-85799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:35:44Z","timestamp":1674808544000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Endothelial-dysfunction-in-patients-with-ankylosing-spondylitis,108996,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"alternative-id":["108996"],"URL":"https:\/\/doi.org\/10.5114\/reum.2019.84815","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]}}}